TGTX EBITDA Growth
Tg Therapeutics Inc · EBITDA Growth
TGTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported37.40%period ending
TGTX TTM EBITDA YoY % (-82.14% → 37.40%)
Year-over-year change
High-resolution chart · PNG
TGTX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 37.4023% | |
| 112.669% | |
| 168.5501% | |
| 1,835.8979% | |
| -9.9873% | |
| 30.6345% | |
| 91.6861% | |
| 148.0003% | |
| 166.1084% | |
| 134.2855% | |
| 113.911% | |
| 94.6019% | |
| 41.3901% | |
| 50.6598% | |
| 45.1324% | |
| 31.7568% | |
| 17.0214% | |
| -2.6022% | |
| -25.411% | |
| -50.6614% | |
| -70.2574% | |
| -70.3246% | |
| -62.8963% | |
| -21.497% | |
| -25.8954% | |
| -9.8064% | |
| 3.6487% | |
| -22.1071% | |
| -6.252% | |
| -25.6481% | |
| -46.4499% | |
| -35.6258% | |
| -42.0105% | |
| -44.0635% | |
| -51.4267% | |
| -53.1103% | |
| -71.0554% | |
| -48.6795% | |
| -25.3585% | |
| -14.0854% | |
| 9.7317% | |
| 1.3305% | |
| -12.737% | |
| -51.7707% | |
| -135.0255% | |
| -167.5273% | |
| -183.3472% | |
| -146.8283% | |
| -90.0376% | |
| -175.4807% | |
| 12.0491% | |
| 25.3038% | |
| 25.3155% | |
| 58.6244% | |
| -157.3589% | |
| -277.0526% | |
| -176.0875% | |
| -171.7489% | |
| -203.9597% | |
| -120.1036% | |
| -310.9151% | |
| -335.2198% | |
| -61.0112% | |
| -99.7154% | |
| 24.0489% | |
| 47.8764% | |
| 59.7404% | |
| 78.4205% | |
| 69.343% | |
| 70.0083% | |
| 63.734% | |
| 52.4134% | |
| 39.117% | |
| -10.8375% | |
| -21.6845% | |
| 37.2966% | |
| 40.5541% | |
| 50.674% | |
| 48.4644% | |
| -226.3383% | |
| -208.8189% | |
| -221.4699% | |
| -220.6804% | |
| -12.8125% | |
| -23.2616% | |
| -19.4418% | |
| -31.638% | |
| -69.8462% | |
| -179.8407% | |
| -240.055% | |
| -154.3456% | |
| -71.1479% | |
| 5.5656% | |
| 52.9964% | |
| 37.9307% | |
| -36,222.4393% | |
| -720.9873% | |
| -76.2283% | |
| 6.2269% | |
| 99.9091% |